Agenus Q2 revenue rises on access and royalty income

Agenus

06/08/2026 12:44

Overview
Immuno-oncology drug developer's Q2 revenue rose yr/yr, driven by higher royalty and access program revenue
Agenus completed $85 mln private placement after quarter-end to fund Phase 3 ROBBIN trial

Outlook
Upfront financing expected to support operations through Q3 2027; warrants may extend funding to 2031

Result Drivers
ACCESS PROGRAM EXPANSION - Co said broader BOT+BAL access programs across more countries and institutions contributed $6.4 mln in Q2 pre-commercial product revenue
COST MANAGEMENT - Co implemented disciplined cost-management measures and prioritized resources for ROBBIN trial execution

Company press release: ID:nBw55sCNsa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Income
 
$11.30 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Agenus Inc is $22.00, about 182.8% above its August 5 closing price of $7.78
The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 6 three months ago

Reuters Recommended Reads
Aug 5 - Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Aug 6 - Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Aug 5 - Arcus Biosciences Q2 revenue falls sharply on lower license income

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)